Under the deal, ViroPharma is also investing in new equipment to increase the manufacturing capacity for Plenadren in order to support commercial product launches across Europe.
Recipharm Stockholm general manager Helene Fehrm said they look forward to building a long term relationship with ViroPharma for its production.
"This investment and the work we are doing for ViroPharma will give us further valuable experience in tablet manufacturing with API in the coating – a unique advantage over conventional approaches – both for Plenadren itself and other customers moving forwards," Fehrm added.
Recipharm is a contract development and manufacturing organisation (CDMO) supplies the global pharmaceuticals market with different products in multiple dosage forms.